Is Tricuspid Regurgitation after TAVR Significant?

Courtesy of Dr. Carlos Fava.

Severe or moderate mitral regurgitation is associated to worse evolution after TAVR. However, we should not forget the tricuspid valve that, even though not extensively researched, is also associated to a negative impact in its evolution.

Más coincidencias de las esperadas entre válvulas bicúspides y tricúspidesA meta-analysis of 12 studies with a total 41485 patients was carried out.

 

Early mortality (up to 6 months) was 1.8 times higher with severe or ≥moderate tricuspid regurgitation (OR, 1.80; 95% CI, 1.01 to 3.19; P=0.05). Between 6 and 30 months after TAVR, it was 1.9 times higher (HR/OR, 1.96; 95% CI, 1.35 to 2.85; P = 0.0004).


Read also: ¿Metformin to Treat Abdominal Aortic Aneurysms?


A second meta-analysis of 7 homogeneous studies was carried out and mortality between 6 and 30 months was 2.25 times higher (HR,2.25; 95% CI, 1.20–4.24; P= 0.01).

 

Conclusion

Significant tricuspid regurgitation (severe or ≥moderate) is associated to an approximate two-fold increase in early or mid-term all-cause mortality in patients with aortic stenosis undergoing TAVR.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Impact of concurrent tricuspid regurgitation on mortality after transcatheter aortic-valve implantation.

Reference: Hisato Takagi, et al. Catheter Cardiovasc Interv. 2018;1–8. DOI: 10.1002/ccd.27948.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...